LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Aratana shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation drug. Aratana told investors that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.”
When this information was revealed to the investing public, the value of Aratana declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.